TY - JOUR
T1 - Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
AU - Gorog, D.A.
AU - Storey, R.F.
AU - Gurbel, P.A.
AU - Tantry, U.S.
AU - Berger, J.S.
AU - Chan, M.Y.
AU - Duerschmied, D.
AU - Smyth, S.S.
AU - Parker, W.A.E.
AU - Ajjan, R.A.
AU - Vilahur, G.
AU - Badimon, L.
AU - ten Berg, J.M.
AU - ten Cate, H.
AU - Peyvandi, F.
AU - Wang, T.T.
AU - Becker, R.C.
N1 - Funding Information:
P.A.G. has received consulting fees and/or honoraria from Bayer, Hikari Dx, Janssen, Medicure, Otitopic, UpToDate and US WorldMeds, and institutional research grants from Amgen, Bayer, Haemonetics, Idorsia, Instrumentation Laboratories, Janssen, the NIH, Medicure, Otitopic and US WorldMeds. H.t.C. is a shareholder of Coagulation Profile and a consultant for Alveron. R.C.B. is a scientific advisor for Basking Biosciences. The other authors declare no competing interests.
Funding Information:
M.Y.C. acknowledges grants from the Ministry of Health, Singapore (CIRG17may014 and MOH-000280). G.V. acknowledges grant PGC2018-094025-B-I00 from the Spanish Ministry of Science, Innovation and Universities. L.B. acknowledges grants from the Spanish Ministry of Science, Innovation and Universities (PID 2019-107160RB-I00) and from Institute of Health Carlos III (CIBERCV CB16/11/00411 and Red TerCel RD16/0011/0018) cofounded by FEDER; Secretaria d’Universitats i Recerca del Departament d’Econo-mia i Coneixement de la Generalitat Catalunya (2017 SGR 1480) and Fundacion Investigacion Cardiovascular-Fundacion Jesus Serra.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/7
Y1 - 2022/7
N2 - Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.In this Consensus Statement, the authors delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess thrombotic risk in these patients. Consensus recommendations are made about the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombosis and in-hospital mortality.
AB - Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.In this Consensus Statement, the authors delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess thrombotic risk in these patients. Consensus recommendations are made about the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombosis and in-hospital mortality.
KW - COMPLEMENT ACTIVATION
KW - COMPLICATIONS
KW - ENDOTHELIITIS
KW - EXTRACELLULAR VESICLES
KW - MANAGEMENT
KW - MECHANISMS
KW - PLATELET
KW - PROTEASE
KW - VENOUS SINUS THROMBOSIS
KW - VON-WILLEBRAND-FACTOR
U2 - 10.1038/s41569-021-00665-7
DO - 10.1038/s41569-021-00665-7
M3 - Article
C2 - 35027697
SN - 1759-5002
VL - 19
SP - 475
EP - 495
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 7
ER -